Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
PharmaNet Development Group Inc (PDGI)
|
Add to portfolio |
|
|
|
| Price: |
$5.02
| | Metrics |
| OS: |
19.5
|
M
| |
-632
|
% ROE
|
| Market cap: |
$98
|
M
| |
|
|
|
Net cash:
|
$61.2
|
M
| |
$3.14
|
per share
|
|
EV:
|
$36.8
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($227)
|
M
| |
|
|
|
EBIT
|
($244)
|
M
| |
|
|
| EPS |
($12.90)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 |
| Revenues | 451.5 | 470.3 | 407.0 | 361.5 | 111.9 | 103.9 | 64.7 | 31.5 |
| Revenue growth | -4.0% | 15.6% | 12.6% | 223.1% | 7.7% | 60.4% | 105.7% | |
| Cost of goods sold | 231.5 | 216.2 | 182.7 | 156.8 | 56.2 | 49.2 | 36.7 | 18.2 |
| Gross profit | 220.0 | 254.1 | 224.3 | 204.7 | 55.6 | 54.6 | 28.0 | 13.3 |
| Gross margin | 48.7% | 54.0% | 55.1% | 56.6% | 49.7% | 52.6% | 43.3% | 42.3% |
| Selling, general and administrative | 121.9 | 114.4 | 98.8 | 83.0 | 29.9 | 30.0 | 17.9 | 7.6 |
| EBIT | -244.1 | 21.5 | 13.0 | 29.8 | 15.0 | 14.6 | 10.1 | 5.8 |
| EBIT margin | -54.1% | 4.6% | 3.2% | 8.3% | 13.4% | 14.0% | 15.7% | 18.3% |
| Pre-tax income | -249.3 | 15.3 | 3.2 | 17.9 | 11.7 | 14.4 | 10.3 | 6.1 |
| Income taxes | 0.1 | 2.3 | -3.6 | 0.2 | 0.4 | 2.8 | 2.4 | 2.3 |
| Tax rate | | 15.3% | | 0.9% | 3.2% | 19.7% | 23.7% | 37.3% |
| Earnings from continuing ops | -251.1 | 12.1 | 6.1 | 17.2 | 11.0 | 11.6 | 7.9 | 3.8 |
| Earnings from discontinued ops | | 0.8 | -42.1 | -12.4 | 8.7 | | | |
| Net income | -251.1 | 12.9 | -36.0 | 4.8 | 19.7 | 11.6 | 7.9 | 3.8 |
| Net margin | -55.6% | 2.7% | -8.9% | 1.3% | 17.6% | 11.2% | 12.2% | 12.1% |
| |
| Diluted EPS | ($12.96) | $0.63 | $0.33 | $0.94 | $0.70 | $0.92 | $0.70 | $0.81 |
| Shares outstanding (diluted) | 19.4 | 19.0 | 18.4 | 18.4 | 15.8 | 12.5 | 11.2 | 4.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|